Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Scopus BioPharma Inc. (SCPS)
USD0.00
+0.00 (+0.00%)
US OTC Healthcare Biotechnology
Address
420 Lexington Avenue 10170
New York City, NY, US
New York City, NY, US
CEO
Alan D. Horsager
Website
scopusbiopharma.com
IPO
2020-12-16
CIK 1772028 ISIN US8091711015
Description
Scopus BioPharma Inc. is a biopharmaceutical company in the clinical development phase, dedicated to pioneering innovative treatments for serious diseases. Its core development programs are concentrated on immuno-oncology gene therapies designed to combat various forms of cancer. The company's offerings include the Duet Platform, which incorporates CpG signal transducer and activator of transcription 3 (STAT3) inhibitors. Another significant product is MRI-1867, a cleverly engineered, orally administered, dual-action hybrid small molecule. MRI-1867 functions as an inverse agonist of the endocannabinoid system's cannabinoid receptor 1 (CB1) and additionally acts as an inhibitor of inducible nitric oxide synthase (iNOS). To advance its key development efforts and other programs, Scopus BioPharma has established strategic collaborations with prominent organizations such as the City of Hope, the National Institutes of Health Program, and The Hebrew University of Jerusalem. Established in 2017, the company was originally named Project18 Inc. before officially rebranding to Scopus BioPharma Inc. in December of that year. Its corporate headquarters are located in New York, New York.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1.4K
Beta
-2.01
Float Shares
34.22M
Free Float %
81.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | -33.33% | +0.00% | +33.33% | -99.20% | -99.99% | -99.99% | -99.99% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.00
DCF (Unlevered)
0.01
+1,081.1%
DCF (Levered)
0.01
+1,081.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-250.87
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+65.8% ★ Q2'23: +58.9% (vs Q2'22)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q2'23: +107.8% (vs Q2'22)
-
Share dilution Biotechnology: -3.4%+22.3% Q2'23: +88.4% (vs Q2'22)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q2'23: 0.00× (vs Q2'22)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|---|
| Revenue |
—
|
—
est.
|
—
est.
|
327.65M
est.
|
| EBITDA |
-11.71M
|
—
est.
|
—
est.
|
—
est.
|
| EBIT |
-11.71M
|
—
est.
|
—
est.
|
—
est.
|
| Net Income |
-11.61M
est: -25.95M (+55.3%)
|
-38.81M
est.
|
-54.42M
est.
|
-28.06M
est.
|
| SGA |
9.03M
|
—
est.
|
—
est.
|
—
est.
|
| EPS |
-0.55
est: -1.23 (+55.3%)
|
-1.84
est.
|
-2.58
est.
|
-1.33
est.
|
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
9
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Dr. Morris C. Laster | 4.93M | 32.90% | 4.93M | — | 4.93M | — | IN | — | 2021-04-07 | ↗ |
| 2 | HCFP/Capital Partners 18B-2 LLC | 3.00M | 14.20% | 3.00M | — | 3.00M | — | OO | Delaware | 2021-08-12 | ↗ |
| 3 | Armistice Capital, LLC | 2.10M | 9.96% | — | 2.10M | — | 2.10M | IA, OO | — | 2022-02-15 | ↗ |
| 4 | Steven Boyd | 2.10M | 9.96% | — | 2.10M | — | 2.10M | HC, IN | — | 2022-02-15 | ↗ |
| 5 | Ira Scott Greenspan | 1.59M | 7.50% | 237.1K | 1.35M | 237.1K | 1.35M | IN | United States of America | 2021-11-26 | ↗ |
| 6 | Joshua R. Lamstein | 1.50M | 7.10% | 151.1K | 1.35M | 151.1K | 1.35M | IN | United States of America | 2021-11-26 | ↗ |
| 7 | HCFP/Capital Partners 18B-1 LLC | 1.35M | 6.40% | 1.35M | — | 1.35M | — | OO | Delaware | 2021-11-26 | ↗ |
| 8 | SCPS/Strategic Capital Partners LLC | 1.07M | 5.60% | 1.07M | — | 1.07M | — | OO | Delaware | 2021-08-12 | ↗ |
| 9 | Marcin Kortylewski, Ph.D. | 911.1K | 5.00% | 911.1K | — | 911.1K | — | IN | United States | 2021-07-13 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
5
Shares acquired
—
Shares disposed
6.15M
Cash buys
—
Cash sales
—
Net activity
-6,150,870
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-11-23 | Lamstein Joshua R | Director / Officer / 10% Owner | J-Other | D | W Warrants | 3,000,000 | 4.00 | 12.00M | 0 | — | ↗ |
| 2021-11-23 | Greenspan Ira Scott | Director / Officer / 10% Owner | J-Other | D | W Warrants | 3,000,000 | 4.00 | 12.00M | 0 | — | ↗ |
| 2021-10-01 | Sanghrajka Ashish P | Director / Officer | — | D | W Warrant | 136,702 | 4.00 | 546.8K | 0 | — | ↗ |
| 2021-10-01 | Lamstein Joshua R | Director / Officer | — | I | W Warrant | 3,000,000 | 4.00 | 12.00M | 0 | — | ↗ |
| 2021-10-01 | Hopper Paul | Director | — | I | W Warrant | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-10-01 | Greenspan Ira Scott | Director | — | I | W Warrant | 3,000,000 | 4.00 | 12.00M | 0 | — | ↗ |
| 2021-10-01 | Gibson Robert J | Director / Officer | — | I | W Warrant | 769,500 | 4.00 | 3.08M | 0 | — | ↗ |
| 2021-08-27 | Lamstein Joshua R | Director / Officer / 10% Owner | P-Purchase | A | Common Stock, par value $0.001 | 200 | 5.00 | 1.0K | 119,997 | — | ↗ |
| 2021-08-27 | Greenspan Ira Scott | Director / Officer / 10% Owner | P-Purchase | A | Common Stock, par value $0.001 | 110 | 4.92 | 541.20 | 82,450 | — | ↗ |
| 2021-08-26 | Lamstein Joshua R | Director / Officer / 10% Owner | P-Purchase | A | Common Stock, par value $0.001 | 200 | 4.90 | 980.00 | 119,797 | — | ↗ |
| 2021-08-24 | Greenspan Ira Scott | Director / Officer / 10% Owner | P-Purchase | A | Common Stock, par value $0.001 | 50 | 4.65 | 232.50 | 82,340 | — | ↗ |
| 2021-08-23 | Greenspan Ira Scott | Director / Officer / 10% Owner | P-Purchase | A | Common Stock, par value $0.001 | 500 | 4.41 | 2.2K | 82,290 | — | ↗ |
| 2021-08-20 | Greenspan Ira Scott | Director / Officer | P-Purchase | A | Common Stock, par value $0.001 | 400 | 4.23 | 1.7K | 81,790 | — | ↗ |
| 2021-08-19 | Lamstein Joshua R | Director / Officer | P-Purchase | A | Common Stock, par value $0.001 | 800 | 4.04 | 3.2K | 119,597 | — | ↗ |
| 2021-08-19 | Greenspan Ira Scott | Director / Officer | P-Purchase | A | Common Stock, par value $0.001 | 2,000 | 4.04 | 8.1K | 13,850 | — | ↗ |
| 2021-08-18 | Greenspan Ira Scott | Director / Officer | P-Purchase | A | Common Stock, par value $0.001 | 1,000 | 4.27 | 4.3K | 11,850 | — | ↗ |
| 2021-08-17 | Greenspan Ira Scott | Director / Officer | P-Purchase | A | Common Stock, par value $0.001 | 1,000 | 4.13 | 4.1K | 10,850 | — | ↗ |
| 2021-07-31 | Lamstein Joshua R | Director / Officer / 10% Owner | J-Other | A | W Warrants | 1,068,016 | 4.00 | 4.27M | 1,068,016 | — | ↗ |
| 2021-07-31 | Greenspan Ira Scott | Director / Officer / 10% Owner | J-Other | A | W Warrants | 1,068,016 | 4.00 | 4.27M | 1,068,016 | — | ↗ |
| 2021-07-27 | Greenspan Ira Scott | Director / Officer | P-Purchase | A | Common Stock, par value $0.001 | 200 | 4.54 | 908.00 | 81,390 | — | ↗ |
| 2021-07-26 | Greenspan Ira Scott | Director / Officer | P-Purchase | A | Common Stock, par value $0.001 | 400 | 4.76 | 1.9K | 81,190 | — | ↗ |
| 2021-07-23 | Lamstein Joshua R | Director / Officer | P-Purchase | A | Common Stock, par value $0.001 | 1,500 | 4.71 | 7.1K | 118,797 | — | ↗ |
| 2021-07-23 | Greenspan Ira Scott | Director / Officer | P-Purchase | A | Common Stock, par value $0.001 | 1,100 | 4.77 | 5.2K | 8,850 | — | ↗ |
| 2021-06-25 | Horsager Alan M | Officer | — | D | Common Stock | 0 | 0.00 | — | 118,200 | — | ↗ |
| 2021-06-01 | Hopper Paul | Director | J-Other | A | Common Stock | 6,333 | 0.00 | — | 0 | — | ↗ |
| 2021-03-31 | Weild IV David | Director | — | D | Stock Options | 100,000 | 5.50 | 550.0K | 0 | — | ↗ |
| 2021-03-31 | Russell Lesley | Director | — | D | Stock Options | 100,000 | 5.50 | 550.0K | 0 | — | ↗ |
| 2021-03-31 | Hofstein Raphael | Director | — | D | Stock Options | 100,000 | 5.50 | 550.0K | 0 | — | ↗ |
| 2021-03-31 | Buckel David A. | Director | — | D | Stock Options | 100,000 | 5.50 | 550.0K | 0 | — | ↗ |
| 2021-03-31 | Battleman David S. | Director | — | D | Stock Options | 100,000 | 5.50 | 550.0K | 0 | — | ↗ |
| 2021-02-25 | Greenspan Ira Scott | Director / Officer | P-Purchase | A | Common Stock, par value $0.001 | 800 | 9.01 | 7.2K | 7,750 | — | ↗ |
| 2021-02-25 | Gibson Robert J | Director / Officer | P-Purchase | A | Common Stock, par value $0.001 | 150 | 9.29 | 1.4K | 300 | — | ↗ |
| 2021-02-24 | Greenspan Ira Scott | Director / Officer | P-Purchase | A | Common Stock, par value $0.001 | 300 | 9.45 | 2.8K | 6,950 | — | ↗ |
| 2021-02-24 | Gibson Robert J | Director / Officer | P-Purchase | A | Common Stock, par value $0.001 | 150 | 9.46 | 1.4K | 150 | — | ↗ |
| 2021-02-23 | Lamstein Joshua R | Director / Officer | P-Purchase | A | Common Stock, par value $0.001 | 500 | 9.34 | 4.7K | 117,297 | — | ↗ |
| 2021-02-23 | Greenspan Ira Scott | Director / Officer | P-Purchase | A | Common Stock, par value $0.001 | 200 | 9.58 | 1.9K | 80,675 | — | ↗ |
| 2021-02-22 | Lamstein Joshua R | Director / Officer | P-Purchase | A | Common Stock, par value $0.001 | 100 | 9.99 | 999.00 | 116,797 | — | ↗ |
| 2021-02-22 | Greenspan Ira Scott | Director / Officer | P-Purchase | A | Common Stock, par value $0.001 | 450 | 10.05 | 4.5K | 5,350 | — | ↗ |
| 2021-02-19 | Lamstein Joshua R | Director / Officer | P-Purchase | A | Common Stock, par value $0.001 | 500 | 10.93 | 5.5K | 116,697 | — | ↗ |
| 2021-02-18 | Greenspan Ira Scott | Director / Officer | P-Purchase | A | Common Stock, par value $0.001 | 2,200 | 10.04 | 22.1K | 4,900 | — | ↗ |
| 2021-02-17 | Greenspan Ira Scott | Director / Officer | P-Purchase | A | Common Stock, par value $0.001 | 200 | 9.81 | 2.0K | 2,700 | — | ↗ |
| 2021-02-16 | Greenspan Ira Scott | Director / Officer | P-Purchase | A | Common Stock, par value $0.001 | 2,500 | 10.20 | 25.5K | 2,500 | — | ↗ |
| 2020-12-16 | Buckel David A. | Director | — | I | Common Stock, par value $0.001 | 0 | 0.00 | — | 5,941 | — | ↗ |
| 2020-12-15 | Sanghrajka Ashish P | Director / Officer | — | D | Common Stock, par value $0.001 | 0 | 0.00 | — | 190,000 | — | ↗ |
| 2020-12-15 | Lamstein Joshua R | Director / Officer | — | D | Common Stock, par value $0.001 | 0 | 0.00 | — | 116,197 | — | ↗ |
| 2020-12-15 | Hopper Paul | Director | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-12-15 | Greenspan Ira Scott | Director | — | D | Common Stock, par value $0.001 | 0 | 0.00 | — | 80,000 | — | ↗ |
| 2020-12-15 | Gibson Robert J | Director / Officer | — | D | Common Stock, par value $0.001 | 0 | 0.00 | — | 2,000 | — | ↗ |
| 2020-04-09 | Lamstein Joshua R | Director / Officer | — | D | Convertible Note | 15,000 | 0.50 | 7.5K | 0 | — | ↗ |
| 2019-09-30 | Sanghrajka Ashish P | Director / Officer | — | D | Stock Options | 300,000 | 3.00 | 900.0K | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
42.08M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
| Filing date | Form type | Filing |
|---|---|---|
| 2023-07-21 | DEF 14A | ↗ |
| 2022-12-02 | PRE 14A | ↗ |
| 2021-12-17 | DEFA14A | ↗ |
| 2021-12-17 | DEFA14A | ↗ |
| 2021-12-16 | DEFA14A | ↗ |
| 2021-12-07 | DEFA14A | ↗ |
| 2021-12-07 | DEFA14A | ↗ |
| 2021-11-24 | DEFA14A | ↗ |
| 2021-11-08 | DEFA14A | ↗ |
| 2021-10-27 | DEFA14A | ↗ |
| 2021-10-08 | DEFA14A | ↗ |
| 2021-09-28 | DEFA14A | ↗ |
| 2021-06-01 | DEFA14A | ↗ |
| 2021-05-27 | DEFA14A | ↗ |
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ira Scott Greenspan | Senior Advisor & Director | 200.0K | male |
| Robert J. Gibson | Vice Chairman, Secretary & Treasurer | 200.0K | male |
| Alan D. Horsager | President?of?Immuno-Oncology and President & Chief Executive Officer of Duet BioTherapeutics | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SCPS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
